Bayer's 2026 Free Cash Flow at Risk from Glyphosate Payments as Tariff Deadline Nears

Bayer's 2025 performance delivered a mixed picture, setting a specific baseline for the year ahead. The company met its upgraded full-year targets, posting currency-adjusted group sales of 45.575 billion euros and a core earnings per share of 4.91 euros. This result, however, came with significant headwinds. A negative currency effect of 1.742 billion euros weighed on the top line, while EBITDA before special items fell 4.5% and net income was deeply negative due to high litigation charges. The financial strain was most visible in the cash flow, where free cash flow declined by 32.9% to 2.084 billion euros.

Looking forward, Bayer's official 2026 outlook is one of stability, but with a major caveat. The company expects stable sales and earnings on a currency-adjusted basis. This is the baseline against which all other pressures, including the looming impact of U.S. tariffs, must be assessed. The primary drag on liquidity will be the glyphosate litigation. The outlook explicitly states that free cash flow will be heavily impacted by settlement payments stemming from the class agreement announced last month. This creates a clear tension: while operational earnings are expected to hold steady, the cash burn from legal obligations will constrain the balance sheet.

Adding to this setup is a leadership transition. Judith Hartmann will take over as CFO in June, following her joining the Board of Management in March. Her arrival marks a new chapter in managing the company's finances through this complex period. The 2026 outlook, therefore, frames the year as a test of execution on a stable core, while navigating a heavy cash outflow from litigation and preparing for the next phase of its turnaround.

The Tariff Landscape and Bayer's Position

The new U.S. trade regime introduces a significant and immediate headwind for Bayer's pharmaceutical business. On April 2, President Trump announced a 100% tariff on patented pharmaceutical products and ingredients under Section 232, citing national security concerns. The tariffs will take effect in 120 to 180 days, targeting imports from key European allies including the European Union, Japan, Korea, and Switzerland. This move is part of a broader push to reshore manufacturing, with specific pathways for a 0% tariff through 2029 for companies that enter into onshoring and pricing deals with the U.S. government.

Bayer's initial reaction is one of strategic composure. A top executive stated on Tuesday that the company saw no need to adjust its 2026 forecasts because of these tariffs. This implies that management believes its current operational plan, which includes potential restructuring or supply chain adjustments, is sufficient to absorb the cost. The company's dual business model-spanning both crop science and pharmaceuticals-adds a layer of complexity. While the tariff directly hits its branded drug sales, its agricultural division may face different trade dynamics, potentially creating a mixed impact across the portfolio.

The bottom line is that the tariff is a new, high-cost variable. For now, Bayer is treating it as a manageable operational issue rather than a fundamental threat to its 2026 outlook. The real test will be execution: whether the company can navigate the 120-180 day window to implement its response without derailing its already-stressed cash flow, which is being heavily consumed by glyphosate litigation.

Financial Impact and Strategic Adjustments

The macro and regulatory pressures are now translating into concrete financial metrics and forcing strategic choices. The primary near-term drag on Bayer's finances is clear: free cash flow will be heavily impacted by settlement payments stemming from the glyphosate class agreement. This is not a minor accounting item; it is a direct cash outflow that compounds the 32.9% decline in free cash flow already seen in 2025. With net financial debt still elevated at nearly 30 billion euros, this cash burn constrains the company's ability to invest in growth or weather further shocks.

Against this liquidity pressure, the new U.S. tariff regime presents a strategic pathway. The 100% tariff on patented pharmaceuticals will hit Bayer's branded drug sales, but the administration has laid out a potential escape hatch. Companies that enter into Most Favored Nation (MFN) pricing agreements with the Department of Health and Human Services and onshoring agreements with the Department of Commerce can qualify for a 0% tariff rate through 2029. This creates a binary choice: either absorb the high cost of imports or commit to significant restructuring and pricing concessions. For Bayer, this adds another layer of complexity to its turnaround, requiring operational agility in a high-stakes negotiation.

This pressure is not uniform across the portfolio. In Crop Science, the 2025 results showed a mixed picture. While the division progressed in its profitability improvement program, fungicides sales declined. This points to regional vulnerabilities, likely in key markets facing economic headwinds or competitive intensification. The stable sales reported for the division overall mask this underlying weakness, indicating that Bayer's agricultural business is not immune to the broader macro cycle of growth and inflation.

The bottom line is that Bayer is navigating a multi-front challenge. It must manage a heavy cash outflow from litigation, strategically respond to a new trade regime with high stakes, and stabilize a business segment showing signs of regional strain. The company's 2026 outlook of stable sales and earnings is a target, not a guarantee, against these converging pressures.

Catalysts, Risks, and What to Watch

The 2026 outlook hinges on a handful of specific, forward-looking events that will determine if stability holds or cracks. For investors, the critical watchpoints are clear.

First is the U.S. government agreement. The 100% tariff is a real threat, but the escape hatch is a binary choice. Bayer must decide whether to enter into the required Most Favored Nation (MFN) pricing agreements with the Department of Health and Human Services and onshoring agreements with the Department of Commerce to secure a 0% tariff rate through 2029. The company has stated it sees no need to adjust forecasts yet, but the clock is ticking. The 120- to 180-day window for implementation is a narrow deadline. Success here would mitigate a major cost headwind, while failure would force a direct hit to branded drug margins and cash flow.

Second is the execution of the glyphosate settlement. The outlook explicitly warns that free cash flow will be heavily impacted by settlement payments. The real test is whether the actual cash outflow aligns with guidance or exceeds it. Given the already-stressed liquidity from the 32.9% decline in 2025 free cash flow and the elevated net financial debt, any shortfall in cash generation would quickly strain the balance sheet. Monitoring the quarterly payment schedule and its impact on the debt-to-EBITDA ratio will be essential.

Finally, the leadership transition in the first half of 2026 adds a layer of strategic uncertainty. Judith Hartmann will take over as CFO in June, following her March appointment. Her arrival is the start of a new chapter in financial management. The key question is whether her capital allocation priorities shift. With litigation payments and potential tariff negotiations demanding cash, any move toward more aggressive cost discipline or a reassessment of growth investments would signal a tightening of the operational screws. The first half will be a period of transition and potential policy calibration.

The bottom line is that 2026 is a year of execution under pressure. The outlook of stable sales and earnings is a target that must be defended against a new trade tariff, a heavy cash outflow from litigation, and a leadership change. The three watchpoints above are the specific metrics and decisions that will reveal if Bayer can navigate this complex setup or if the outlook will need a downward revision.